Doxorubicin + Fluorouracil + Methotrexate + Thiotepa + Vinblastine

This is a combination chemotherapy regimen that has been studied for advanced breast cancer. From the information provided, this appears to be a variation or component of several treatment protocols mentioned in the search results, particularly related to the VATH regimen (vinblastine, doxorubicin, thiotepa, and halotestin) which was compared with CAF (cyclophosphamide, doxorubicin, and fluorouracil) in clinical trials. The combination includes several chemotherapeutic agents: - Doxorubicin (also known as Adriamycin): an anthracycline antibiotic that inhibits DNA and RNA synthesis - Fluorouracil: an antimetabolite that interferes with DNA synthesis - Methotrexate: an antimetabolite that inhibits dihydrofolate reductase - Thiotepa: an alkylating agent - Vinblastine: a vinca alkaloid that inhibits microtubule assembly This specific five-drug combination as presented doesn't appear to have a standard acronym or brand name in the search results, though components of it appear in regimens like VATH, TAVH, and M-Vac. The search results show that these types of combination chemotherapy regimens were studied for metastatic breast cancer, with clinical trials comparing different combinations for response rates, time to treatment failure, and survival outcomes. Some of these combinations were also considered as second-line regimens for patients who had failed prior systemic therapy. The information suggests this is a pharmaceutical combination chemotherapy regimen consisting of multiple small molecule drugs used in oncology, particularly for advanced breast cancer treatment.